ArticleCurrent medicinal chemistry2026
Clinical Significance of RBM15 in Gastric Cancer: A Multi-Database Validation.
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundGastric Cancer (GC) represents a highly prevalent and aggressive form of malignancy. Recent scholarly endeavors have implicated the RNA binding motif protein 15 (RBM15) gene in the onset and progression of cancer. The present study was designed to delve into the expression profile of RBM15 in GC, assess its prognostic significance, and explore its potential as a viable therapeutic target.
methodsIn this investigation, we conducted a comprehensive analysis of multiple facets related to the gene RBM15 in GC samples utilizing publicly accessible databases, including TCGA, GEPIA, TIMER, HPA, Kaplan-Meier Plotter, CPADS, and BEST. Specifically, we examined the mRNA expression levels, clinicopathological characteristics, and survival prognosis, conducted gene function enrichment assessments, analyzed mutation profiles, performed immune cell infiltration evaluations, and assessed drug sensitivity. Notably, all parameters employed in the online databases adhered to their respective default settings.
resultsThe expression of RBM15 mRNA is upregulated in GC and exhibits a correlation with a favorable prognosis, with an HR of 0.74 (95% CI = 0.62-0.88, p = 0.00054). Specifically, its expression is notably higher in tumor tissues compared to normal tissues. Furthermore, RBM15 expression is associated with differences in pTNM stage, gender, and racial disparities in survival outcomes. Functionally,
conclusionRBM15 mRNA is upregulated in GC and significantly associated with a favorable prognosis. It correlates with clinicopathological features, is enriched in DNA replication processes, and is commonly mutated. Its expression also impacts immune cell infiltration and drug sensitivity, indicating its potential as a prognostic marker and therapeutic target in GC.
Indexed as
Identifiers
40051357What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.